Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 27, 2006

Boehringer Ingelheim to Develop and Commercialize Biota’s HCV Candidate in Deal Worth $102M

  • Biota Holdings entered into a worldwide research collaboration and licensing agreement with Boehringer Ingelheim to develop and commercialize Biota's nucleoside analogues designed to treat hepatitis C virus (HCV) infections and potentially other diseases.

    Under the terms of the agreement, Biota is eligible to receive payments up to $102 million based on products achieving certain clinical, regulatory, and commercialization milestones, including an initial technology access fee and research support. In addition, Biota would receive royalties on future sales of licensed products marketed by Boehringer Ingelheim. 

    Biota is responsible for drug discovery research and Boehringer Ingelheim is responsible for worldwide development of potential compounds and their commercialization. Biota and Boehringer Ingelheim will be equally represented on the joint research committee to oversee and coordinate the activities of the program.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »